Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 to enhance regulatory T cells in newly diagnosed ALS
2015-005347-14Phase 2Unknown
- Sponsor
- CHU Nîmes
- Start
- May 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of aldesleukin in amyotrophic lateral sclerosis (ALS), sponsored by CHU Nîmes. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2015-005347-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005347-14.